TEC Edmonton helps researchers protect, develop and commercialize new technologies.

New Grants

NSERC I2I Phase I grant

TEC Edmonton has worked with Dr. James Harynuk in securing an NSERC I2I Phase I grant worth $125,000 to further the Harynuk group’s arson research and develop a fully fledged commercial prototype software package for arson investigation that will be subjected to ongoing testing and validation in the RCMP Forensics Laboratory.

Moreover, in order to prove that the core aspect of the software can be used for a variety of applications beyond arson investigations, the group will work towards demonstrating that their technology can improve offerings for automated identification of bacteria, which will open doors to many other opportunities.

Previously TEC Edmonton had been awarded with an NSERC I2I Market Assessment grant for this project, the outcome of which formed part of the successful Phase 1 application.

It was what you could realistically call a ringing endorsement of TEC Edmonton’s new TEC Health Accelerator, from Canada’s top health care investment banking firm, no less.

“Quite frankly, we first came to Edmonton secretly dreading the pitch we thought we’d hear from TEC,” said Brian Bloom, co-founder and president of Canada’s leading health care investment house, Bloom Burton & Co. Bloom was the keynote speaker at the launch of the TEC Edmonton TEC Health Accelerator, Nov. 27, 2014 in Edmonton.

Bloom is not one to pull his punches. “We regard many such (accelerator) projects as massive wastes of public dollars, as sinkholes of money. But TEC Edmonton’s TEC Health Accelerator is doing the right things. This is all about supporting winners, providing advisory services, mentoring, creating market awareness, networks and introductions so the cream can rise to the top.

“This is what accelerators should be doing, creating a faster path for the best companies to grow.”

Brian Bloom and Jolyon Burton have worked together for more than 12 years, and they formed Bloom Burton & Co. in 2008. Bloom Burton raises capital for health care companies, offers merger and acquisition advisory services, provides equity research with “analysts who aren’t afraid to call crap ‘crap’ and good stuff, ‘good stuff’ ”, directly invests in companies, and supports company creation and incubation through its consulting work.

Academic commercialization, bringing ideas and innovation to market that will ultimately improve health care delivery to patients, isn’t that hard to figure out, Bloom said.

Commercialization of health research should have higher priority within universities, he said. “Only a small sliver of academic curiosity-driven research has some commercial potential to start with.”

Industry and investors, he says, should be actively engaged with faculty researchers and inventors to determine market needs. Researchers and inventors, Bloom said, should be rewarded for their interest in commercialization. “Commercialization shouldn’t work against a researcher. It should count towards tenure.”

The $64,000 question in his business, said Bloom, is trying to judge the future, given the commercialization process takes years and years. “What the cholesterol market will look like in 10 years is a qualitative judgement. Trying to calculate value is tough!!”

In his talk, Bloom had fun dispelling myths about academic commercialization.

“They say ‘commercialization is difficult.’ Well it’s supposed to be difficult.

“ ‘Government should do more.’ Government already does a lot!

“ ‘The ‘valley of death’ is killing great ideas. Not it’s not! The ‘valley of death’ is a lovely place for ideas to shrivel up and die. Extraordinary ideas don’t die. They eventually find funding and support.

“As for the notion that there’s no money out there … the truth is there’s more money than there are good ideas worth investing in.”

He’s blunt. “Ninety percent of basic scientific research has no commercial potential. And most of the remaining 10% have the wrong plan to market or the wrong people. This can be fixed! This is where TEC Edmonton TEC Health Accelerator can contribute.”

His praise holds high value. “Bloom Burton will be working closely with the TEC Edmonton’s TEC Health Accelerator,” says Bloom. “We’re proud to be strategic partners.

“I would not attach our company’s name to any organization that we had any doubts about. We think the TEC Health Accelerator business model has got it right.”

Posted: Apr 3, 2019

A Novel Method to Produce Pitched Kefir for Reducing Cholesterol

Description Researchers at the University of Alberta and TEAGASC have jointly developed a pitched-based method to produce kefir (a fermented milk beverage) that when consumed reduces blood cholesterol levels. The......


Posted: Nov 5, 2018

Novel F-18 Beta-Hydroxybutyric Acid Radiotracers for PET Imaging

Description Researchers at the University of Alberta have synthesized novel beta-hydroxybutyric acid radiotracers for PET imaging using a 3 step radiosynthetic process. The compounds are designed to serve as radiofluorinated......


Posted: Nov 5, 2018

A Novel Method for CryoPreservation of Cells in Monolayers

Description Researchers at the University of Alberta have developed a novel method to cryopreserve cells while adhered in a monolayer configuration. This method can preserve cells on a substrate and......


Posted: Oct 30, 2018

Train-Triggered Alert System for Conditioning and Warning Wildlife

Description Researchers at the University of Alberta have developed a novel, inexpensive, and compact system to alert wildlife to approaching trains, increasing the time available to avoid a collision. Rail-caused......


Posted: Oct 19, 2018

New Topical Therapy for Melanoma

Description Dr. Afsaneh Lavasanifar and collaborators have developed a PCBCL–b-PEG-b-PCBCL (PolyGelTM) hydrogel formulation of silibinin which provides enhanced skin permeabiity and delayed release of silibinin under physiological conditions. In vitro......


Posted: Aug 2, 2018

Novel FOXM-1 inhibitors for diagnosis and treatment of cancer

Description Researchers at the University of Alberta are utilizing their new insights into the mechanism of action of FOXM-1 inhibitors to design first in class oncology drugs targeting FOXM-1 protein.......


Posted: Aug 2, 2018

Novel SERS-Based Biosensing platform for prostate cancer

Description Researchers at the University of Alberta have developed biogenic silver nanoparticles which can be used as plasmonic labels for enhanced spectroscopy applications. The nanoparticles can be modified with Raman......


Posted: Mar 29, 2018

Hand-Held Device and Computer-Implemented Steering of a Percutaneously Inserted Needle

Description Dr. Mahdi Tavakoli and his team at the University of Alberta have developed a novel hand-held device and methods to enable real-time assisted steering of percutaneously inserted needles, such as......


Posted: Mar 20, 2018

Novel Radiation-Responsive Nanoparticles for Biomedical Applications

Description Researchers at the University of Alberta in collaboration with Lakehead University have developed novel radiation-responsive block polymers for drug delivery. The nanoparticles are modified poly-L-glutamic acid (m-PGA) polymers which......


Posted: Mar 13, 2018

Flow Cytometry Sensing Using Diffracted Orders of a Grating

Description Flow cytometry is a useful tool that employed in diagnoses of various blood diseases, basic research, clinical trials or even as a “cell sorter” instrument. Currently, flow cytometry involves......


Posted: Mar 13, 2018

Off-Axis Spiral Phase Mirrors To Create Vortex Beams

Description There has been an increased interest in taking advantage of the orbital angular momentum properties of light via helical wavefronts for various applications in manufacturing, imaging, and communications. By......


Posted: Mar 6, 2018

Allyl Monomers And Polymers From Glycerol

Description In recent years, with the rapid expansion in biodiesel production, the biodiesel industry is facing the dilemma, on the one hand, of how to meet an ever-growing biofuel demand,......